Last reviewed · How we verify
BL capsule
BL capsule is a traditional Chinese medicine formulation that modulates immune and inflammatory pathways to treat respiratory and digestive conditions.
BL capsule is a traditional Chinese medicine formulation that modulates immune and inflammatory pathways to treat respiratory and digestive conditions. Used for Respiratory conditions (specific indication not publicly detailed), Gastrointestinal conditions (specific indication not publicly detailed).
At a glance
| Generic name | BL capsule |
|---|---|
| Sponsor | Henan University of Traditional Chinese Medicine |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Gastrointestinal |
| Phase | Phase 3 |
Mechanism of action
As a Chinese herbal medicine product, BL capsule likely contains multiple botanical ingredients that work synergistically to regulate immune function and reduce inflammation. The exact molecular mechanisms are not well-characterized in Western pharmacological terms, but traditional use suggests effects on respiratory tract health and gastrointestinal function.
Approved indications
- Respiratory conditions (specific indication not publicly detailed)
- Gastrointestinal conditions (specific indication not publicly detailed)
Common side effects
Key clinical trials
- A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo (PHASE3)
- The Impact of Selected Probiotic Bacteria on Gut Microbiota, Stress Indicators and Nutritional Status of Young Adults (NA)
- Probiotic Intervention for Microbiome Modifications and Clinical Improvements in Fragile X Syndrome (NA)
- BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women. (PHASE3)
- Probiotic BL NCC 2705 and Gluten Sensitivity (NA)
- Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD (PHASE3)
- Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective Study (PHASE4)
- Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BL capsule CI brief — competitive landscape report
- BL capsule updates RSS · CI watch RSS
- Henan University of Traditional Chinese Medicine portfolio CI